ASAP3

Across TCGA pan-cancer cohorts, ASAP3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ASAP3 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASAP3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ASAP3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ASAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.777	0.936	.006	22	view →
GBM	OS	Median	All	0.369	0.656	.009	10	view →
LSCC	OS	Median	II,III,IV	0.872	1.000	.009	10	view →
HNSC	DFS	Median	IV	0.903	0.695	.036	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ASAP3–PDAC (OS)

Open the PDAC breakdown →